# Translate Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/translate-bio

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.translate.bio
- Total disclosed funding: $129M
- Latest round: Series C (Dec 22, 2016)
- Investors on record: 13

## About

Translate Bio, Inc. is a biotechnology company focused on developing messenger RNA (mRNA) therapeutics to treat diseases, leveraging innovative approaches in genetic medicine.Translate Bio, Inc. specializes in mRNA therapeutics, founded in 2011 and headquartered in Lexington, US. The company has undergone strategic pivots and was acquired by Sanofi S.A. in a Trade Sale for USD 3.2 billion. The CEO is Rana Latif, who has a strong background in the industry. The firm has raised a total of USD 3.2 billion, with the most recent deal occurring on 2019-09-19.Translate Bio, Inc. focuses on mRNA therapeutics, crafting solutions aimed at treating various diseases. The company develops innovative therapies that harness the potential of mRNA technology, targeting unmet medical needs and offering promising avenues for treatment.In 2020, Translate Bio, Inc. reported a revenue of USD 138.81 mn, with an EBITDA of USD -46.05 mn, reflecting its ongoing investment in research and development within the biotechnology sector.Translate Bio, Inc. plans to leverage its recent acquisition by Sanofi S.A. to expand its product offerings in mRNA therapies, targeting new disease areas by mid-2022. The recent funding of USD 3.2 billion will be directed towards accelerating the development of its therapeutics pipeline and expanding into international markets.

## Funding rounds

- Series C, Dec 22, 2016, $51M — Atlas Venture, Baupost Group, SR One, Fidelity Investments, Omega Funds, MRL Ventures Fund
- Series B, Jul 23, 2015, $55M — Atlas Venture, Baupost Group, Brookside Capital Partners, SR One, Merck Global Health Innovation Fund, Leerink Partners LLC, Monsanto Company, Omega Funds, Pfizer Venture Investments, Mass General Brigham Ventures, Rock Springs Capital
- Series A, Jan 18, 2012, $21M — Atlas Venture, SR One, Monsanto Company, Mass General Brigham Ventures
- Series A, Nov 30, 2011, $2.7M — Atlas Venture

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B, Series C
- Monsanto Company — Series A, Series B
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B
- Baupost Group — Series B, Series C
- Brookside Capital Partners (https://capitalatlas.ai/funds/brookside-capital-partners) — Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series B
- Leerink Partners LLC — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B, Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- Rock Springs Capital — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series C